Efficacy of GSK Biologicals' Candidate Malaria Vaccine 257049 Against Malaria Disease in Infants and Children in Africa

PHASE3CompletedINTERVENTIONAL
Enrollment

15,459

Participants

Timeline

Start Date

March 27, 2009

Primary Completion Date

March 1, 2011

Study Completion Date

January 31, 2014

Conditions
Malaria
Interventions
BIOLOGICAL

Malaria Vaccine 257049

administered intramuscularly into the left deltoid.

BIOLOGICAL

Meningococcal C Conjugate Vaccine

administered intramuscularly into the left deltoid.

BIOLOGICAL

Cell-culture rabies vaccine

administered intramuscularly into the left deltoid.

BIOLOGICAL

TritanrixHepB/Hib

administered intramuscularly into the left deltoid.

BIOLOGICAL

Polio Sabin Oral Polio Vaccine (GSK)

administered orally.

Trial Locations (10)

80108

GSK Investigational Site, Kilifi

Unknown

GSK Investigational Site, Ouagadougou

GSK Investigational Site, Lambaréné

GSK Investigational Site, Kintampo

GSK Investigational Site, Kumasi

GSK Investigational Site, Kisumu

GSK Investigational Site, Lilongwe

GSK Investigational Site, Maputo

GSK Investigational Site, Dar es Salaam

GSK Investigational Site, Tanga

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

The PATH Malaria Vaccine Initiative (MVI)

OTHER

lead

GlaxoSmithKline

INDUSTRY